As 2013 draws to a close, I've decided to stick my neck out and make some predictions for 2014. Perhaps I'll get lucky and a few will even come true! After several mental experimentations on the structure, I'll settle for stepping roughly past each major player.
Tuesday, December 31, 2013
Tuesday, December 17, 2013
It was very gratifying to get comments on my recent piece on a de novo assembly review from both a referee of the manuscript (the amazing Heng Li) as well as one of the authors of the piece (though I am truly feeling guilty I forgot to reach out to the authors). Of course I was having my usual post-post regrets of things not written, such as the whole interesting topic of dealing with (and leveraging) uneven coverage in metagenomes and when assembling from amplified samples. But one other thing I was reminded of is one of the minor complaints I have with assembly programs: a lack of proper handing of circular genomes.
Sunday, December 15, 2013
A review on short-read de novo genome assembly appeared recently in PLoS Computational Biology, titled "Next-Generation Sequence Assembly: Four Stages of Data Processing and Computational Challenges". I think the review has a number of merits, but I also find a number of frustrating flaws. I'm going to write this entry much as I would have written a referee report on it. Unfortunately, that will mean I'll dwell a bit more on the flaws than the assets, but if you are interested in the field
Friday, November 15, 2013
So, this piece is going to be mostly asking questions. In one of the corners of my dream world I have a scientific historian on retainer, but in the real world my substitute is to throw some questions out and hope some knowledgeable people leave comments. If someone I spark someone’s term paper or thesis topic, I ask only that I get an electronic draft!
Friday, October 25, 2013
In the movie The Spanish Prisoner, a brilliant inventor possesses a paranoia that "The Process" he has invented will be stolen by deceitful competitors, and everyone speaks with a highly distinctive cadence. The entire movie is suffused with deceit, starting with the title which is a notorious con scheme akin to the modern Nigerian scam. I spent last evening in some of the space in which the movie was filmed listening to a scientist in that mold (& distinctive speech) describe a process his group has invented (indeed, by lucky chance I helped him find the venue). But many remain unconvinced that Clive Brown and Oxford Nanopore are not themselves the puller of ocular wool.
Tuesday, October 22, 2013
I haven't talked about Ion Torrent for a while, because it was largely off my radar screen. In early 2012 the PGM had been an important contributor to my early de novo genome assemblies, as it was the only fast turnaround, low cost system I could access. But the data quality was always frustrating, with many indels, and the 200 basepair mode on the read lengths not great for assembly. Once I could access a MiSeq, that became our dominant instrument for individual genome assembly. We tried Ion once more with the 300 basepair chemistry, but were not particularly impressed.
Saturday, October 19, 2013
Roche's announcement this week that they planned to shut down the 454 sequencing business in mid-2016 was not completely unexpected, as a number of rumors of shutdown had shown up on Twitter. Most tweets on the subject fell into two categories: either just-the-facts-ma'am or jokes about the dominant error profile (which I guess you could call just the facts maaa'aaam). But, certainly I wouldn't have thought Roche on the verge of this decision when I went to AGBT 2013 in February, as 454 had a huge suite in a prime location (just by the main conference hall entrance) and many expensive events. Now, Roche's presence in the genomics space is looking like just the recently announced deal with PacBio to market human diagnostics on that platform.
Thursday, September 26, 2013
One of the two big buzzes in the genomics business world was the announcement that Roche Diagnostics has signed a major deal with Pacific Biosciences in the field of human diagnostics, which comes with a $35M upfront payment and a possible $45M in milestones, plus future sales of reagents. PacBio stock rocketed over 70% on this news. This on the same day that cancer diagnostics company Foundation Medicine went public with a similar potent climb from their offering price; a good day for those lucky enough to have the shares (which, by the way, does not include me in any way, though Foundation shares a common venture backer with Warp Drive Bio in Third Rock Ventures).
Monday, September 23, 2013
Over at Homolog.us there are two detailed blog entries on Pacific Biosciences entitled "End of Short Read Era?" (Part I and Part II). I've tweeted a number of comments on the technical aspects, but there are some more substantial thoughts reading these pieces helped me condense.
Saturday, August 24, 2013
Sunday, June 30, 2013
LinkedIn has a feature by which one can endorse other people for different fields. Periodically the system prompts me to vote yea-or-nay on a bunch of endorsements, and conversely I get regular updates as to what others have endorsed me. It's always nice to get a vote of confidence, but sometimes I find myself wondering what it really means.
Thursday, May 16, 2013
I've been thinking about this piece for a while, because I am a frequent presence on SEQAnswers.com and often dive into questions regarding de novo sequence assembly, particularly for small genomes. It's good to help out and a way to feel like one is contributing to a broader community, but sometimes it can be very frustrating because the seekers (SEQers?) of help do not post their questions very well. So, it would be helpful to have a post to point them to, though I'm sure there are considerations I either haven't thought of or will fail to remember to add. So, those can either go into the comments or a future post, or perhaps something can go in the Wiki at SEQAnswers.
But in general, think of it this way: you have some experienced hands in a field you wish to enter, who are willing to give detailed advice for free. But, they can't give that advice unless you specify your question well, and if you don't get it right the first time they may not see (or may ignore) your second shot.
Wednesday, April 24, 2013
The big sequencing platform news this week is Roche's announcement that they are ending their collaborations aimed at developing new sequencing technologies. A collaboration with DNA Electronics aimed to create an Ion Torrent-like system whereas a more ambitious effort with IBM aimed to create instruments based on "DNA transistors". As noted by Forbes' Matthew Herper in a thought-provoking piece, Illumina is sitting very high atop the sequencer market.
Thursday, April 04, 2013
I've been mulling this item ever since AGBT, but have struggled with the title. I don't want to sound like I have a grudge against 454 ( truth is I just got some good datasets off this technology), but I do believe that they are few papers away from being stampeded. Or perhaps not; perhaps the community is really wedded to this platform.
Monday, March 04, 2013
Back-of-the-envelope calculations can be quite useful, but also quite dangerous. They are meant to be quick estimates, but can't be taken too seriously. Still, I try to get them right & deeply regret overestimating recently on Twitter the cost of a human genome on PacBio by 3X. Twitter is particularly dangerous: tempting to fire off a note, but impossible to pack in the full calculation
Tuesday, February 26, 2013
As others have noted, a significant theme at AGBT this year was sequencing at length. While this year lacked true bombshells, PacBio impressed many with their making single-contig bacterial genome assemblies look easy. Moleculo had been the object of much pre-meeting excitement, and while very few additional details emerged about their process, several talks showed what could be done. As I have discussed previously, Nabsys demonstrated their “positional sequencing” system to select invitees in a hotel suite. Optical mapping from OpGen and BioNano Genomics featured in a few posters, but did not attract much attention. Oxford Nanopore had no physical presence, beyond a somewhat secretive suite, but several ONT staffers were happy to reiterate their confidence that they will launch their system – when it is good and ready.
Friday, February 22, 2013
Monday, February 18, 2013
A complaint which seems to be circulating on Twitter and elsewhere is that this year’s AGBT conference on Marco Island next week doesn’t look like it will have any excitement around new platforms. AGBT has been a traditional coming out party for platforms. Last year it was Oxford Nanopore which created a huge buzz, and in previous years that crown has been held by Ion Torrent, Pacific Biosciences, Complete Genomics and others (including a few which seem to have gone kaput).
It is hard to argue that this year’s program is much more heavily tilted towards applications of genomics than novel genomic technologies. Many of the genomic technology talks are updates on the evolution of existing platforms such as PacBio and Illumina (especially the Moleculo technology). But, there will also be novel technologies.
This past fall I had the pleasure of spending half a day with the folks at Nabsys, located a short distance from Boston in Providence RI. Nabsys’s buildings are in a sea of drab parking lots (not to mention sheriff’s cars; a courthouse is nearby), but on the interior were quite pleasant. I was largely wearing my “day job” hat that day, but Nabsys will be unveiling their instrument at AGBT and has given me permission to talk about what I saw (and reviewed what I've written to make sure I didn't make some dumb errors, though the content is all mine). Of course, I will update this after I look some more at AGBT.
Saturday, February 16, 2013
Friday, February 15, 2013
I was originally going to start this with a joke alluding to one of the signature special effects of Star Trek: The Next Generation, but given the recent events in Russia it's probably in poor taste to speak lightly of flashes in the sky. But, after much preparation, today was the day that Warp Drive Bio completed packing up, with next week ushering in our new facility.
Monday, January 14, 2013
As one might guess from reading this space, I always have an itch to try new sequencing technologies or updates to existing ones. That's generally a good thing in my position, though more than a few times I experience buyers remorse. At least this time, I found something a bit interesting
Thursday, January 10, 2013
As the clear leader in the genome sequencing technology market, Illumina is often in the news. As befitting the winter season, there's just been a blizzard of Illumina news, mostly announcements from within but also two important external ones (an excellent summary of these can be found at NextGenSeek).